Clinical trials: Adjuvant Treatment
Breast Cancer
Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer
Recent clinical studies showed that triple-negative breast cancer patients (ER-/PR-/HER2-) may benefit more from Capecitabine chemotherapy.
- Trial name
- NCT01642771
- Testing
- 5-Fu/epirubicin/CTX following Docetaxel, Docetaxel/capecitabine followed by XEC
- Where
- 37 sites in China
- Volunteers
- 636 people
- Sponsor
- China Breast Cancer Clinical Study Group
Rhegmatogenous Retinal Detachment
Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment
26 patients presenting a rhegmatogenous retinal detachment with more than 4 days of duration will be prospectively included. A single dose of ursodeoxycholic acid will be administered orally before surgery at different…
- Trial name
- UDCA-RD (NCT02841306)
- Testing
- Ursodeoxycholic Acid
- Where
- Switzerland
- Volunteers
- 26 people
- Sponsor
- Francine Behar-Cohen
Prostate Cancer
Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy after surgery may kill more tumor cells.
- Trial name
- NCT00003858
- Testing
- mitoxantrone hydrochloride
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatocellular Carcinoma
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
The purpose of this study is to evaluate the safety and efficacy of administration of intratumoral IP-001 injection at different dosages (volume and concentration) following local microwave ablation (MWA) or surgical resection…
- Trial name
- NCT06526338
- Testing
- 1.0% IP-001 for injection, Surgical Resection and Local Ablation, Local Ablation Alone
- Where
- United States
- Volunteers
- 315 people
- Sponsor
- Robert C. Martin
Otitis Media
Acute Otitis Media: Adjuvant Therapy to Improve Outcome
Acute otitis media is one of the most common diseases of childhood and is one of the major causes of hearing loss in children. Despite the availability of effective antibiotic therapy for otitis media, treatment failures…
- Trial name
- NCT00000363
- Testing
- Antihistamine, Corticosteroid
- Where
- United States
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Stage III Ovarian Cancer, Stage IV Ovarian Cancer
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced…
- Conditions
- Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- CRS/HIPEC (NCT02124421)
- Testing
- Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Mercy Medical Center
Breast Cancer
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy
The current trial, BNIT-BR-003, will evaluate the safety and biological activity of a fixed dose of MVA-BN®-HER2 following adjuvant chemotherapy in patients with HER-2-positive breast cancer.
- Trial name
- NCT01152398
- Testing
- MVA-BN-HER2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Bavarian Nordic
Melanoma (Skin)
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00089193
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- 5 sites in United States
- Sponsor
- Craig L Slingluff, Jr
Breast Neoplasm
Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women
The purpose of this study is to examine the effect of the combination of everolimus and letrozole compared to placebo and letrozole as pre-surgical therapy in patients with newly diagnosed estrogen receptor positive breast cancer.
- Trial name
- NCT00107016
- Testing
- RAD001, Letrozole 2.5mg, Letrozole 2.5mg
- Where
- 46 sites in United States, Austria and 8 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma
Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma
Neoadjuvant plus adjuvant treatment with target therapy and immunotherapy given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma (stage…
- Trial name
- NEO-TIM (NCT04722575)
- Testing
- Cobimetinib 20 MG Oral Tablet, Vemurafenib 240 Mg Oral Capsule, Atezolizumab 1200 MG in 20 ML Injection
- Where
- 6 sites in Italy
- Volunteers
- 95 people
- Sponsor
- Fondazione Melanoma Onlus
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
COVID-19 Respiratory Infection
HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
- Trial name
- NCT04986176
- Testing
- HC-1119
- Volunteers
- 602 people
- Sponsor
- Applied Biology, Inc.
Colorectal Liver Metastasis
Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II Study
Pts with histologically confirmed CRLM and whose CRS >2 were enrolled into this single-arm, phase II study. The critical enrollment criteria were that Subjects had completely resected Primary lesion and liver metastases and had…
- Trial name
- NCT05753163
- Testing
- HAIC-FOLFOX combined with Sintilimab and Regorafenib
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Adjuvant Chemotherapy
Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients
This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.
- Trial name
- NCT06389552
- Where
- South Korea
- Volunteers
- 36 people
- Sponsor
- HK inno.N Corporation
Nasopharyngeal Cancer, Chemotherapy
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to chemo-radiotherapy could further decrease the rate of disease progression and improve the…
- Conditions
- Nasopharyngeal Cancer, Chemotherapy, Radiotherapy, PD-1 Therapy
- Trial name
- NCT04453826
- Testing
- Camrelizumab plus chemo-radiotherapy, Chemo-radiotherapy alone
- Where
- 6 sites in China
- Volunteers
- 388 people
- Sponsor
- Sun Yat-sen University
Colo-rectal Cancer
PTC Drug Sensitivity Detection to Guide Postoperative Adjuvant of Colorectal Cancer
The research objectives is to compare vitro 3D drug sensitivity test results of micro tumor (PTC) with the clinical outcomes of patients, evaluate the consistency between the test results of the technology platform and the…
- Trial name
- NCT05978349
- Testing
- adjuvant therapy based on 3D drug sensitivity test results of micro tumor (PTC) in vitro
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Peking Union Medical College Hospital
Coagulation
Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy
The main objective of this study is to assess the effectiveness of low dose Vitamin K1 (200 micrograms per day) at improving anticoagulation control in unstable patients on warfarin.
- Trial name
- LOCK (NCT00794755)
- Testing
- Vitamin K1 (Phytonadione)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Choroidal Melanoma
Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma
To report preliminary results on safety and tolerability of intravitreal injection of Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green (ICG)-based photodynamic therapy (PDT) in the…
- Trial name
- NCT00680225
- Testing
- Ranibizumab injection and TTT - ICG based
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- New England Retina Associates
HER2-positive Breast Cancer
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after…
- Trial name
- NCT06830889
- Testing
- BL-M07D1, T-DM1
- Where
- 2 sites in China
- Volunteers
- 1,450 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.